key: cord-0824398-15zg78xy authors: Hoertel, Nicolas; Sánchez‐Rico, Marina; Vernet, Raphaël; Beeker, Nathanaël; Neuraz, Antoine; Alvarado, Jesús M.; Daniel, Christel; Paris, Nicolas; Gramfort, Alexandre; Lemaitre, Guillaume; Salamanca, Elisa; Bernaux, Mélodie; Bellamine, Ali; Burgun, Anita; Limosin, Frédéric title: Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study date: 2021-03-10 journal: Br J Clin Pharmacol DOI: 10.1111/bcp.14784 sha: 992be0373349f9c32c20177e07179399c983de8b doc_id: 824398 cord_uid: 15zg78xy AIMS: To examine the association between dexamethasone use and mortality among patients hospitalized for COVID‐19. METHODS: We examined the association between dexamethasone use and mortality at AP‐HP Greater Paris University hospitals. Study baseline was defined as the date of hospital admission. The primary endpoint was time to death. We compared this endpoint between patients who received dexamethasone and those who did not in time‐to‐event analyses adjusted for patient characteristics (such as age, sex and comorbidity) and clinical and biological markers of clinical severity of COVID‐19, and stratified by the need for respiratory support, i.e. mechanical ventilation or oxygen. The primary analysis was a multivariable Cox regression model. RESULTS: Of 12 217 adult patients hospitalized with a positive COVID‐19 reverse transcriptase–polymerase chain reaction test, 171 (1.4%) received dexamethasone orally or by intravenous perfusion during the visit. Among patients who required respiratory support, the end‐point occurred in 10/63 (15.9%) patients who received dexamethasone and 298/1129 (26.4%) patients who did not. In this group, there was a significant association between dexamethasone use and reduced mortality in the primary analysis (hazard ratio, 0.46; 95% confidence interval 0.22–0.96, P = .039). Among patients who did not require respiratory support, there was no significant association between dexamethasone use and the endpoint. CONCLUSIONS: In this multicentre observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID‐19 requiring respiratory support. stratified by the need for respiratory support, i.e. mechanical ventilation or oxygen. The primary analysis was a multivariable Cox regression model. Results: Of 12 217 adult patients hospitalized with a positive COVID-19 reverse transcriptase-polymerase chain reaction test, 171 (1.4%) received dexamethasone orally or by intravenous perfusion during the visit. Among patients who required respiratory support, the end-point occurred in 10/63 (15.9%) patients who received dexamethasone and 298/1129 (26.4%) patients who did not. In this group, there was a significant association between dexamethasone use and reduced mortality in the primary analysis (hazard ratio, 0.46; 95% confidence interval 0.22-0.96, P = .039). Among patients who did not require respiratory support, there was no significant association between dexamethasone use and the endpoint. Conclusions: In this multicentre observational study, dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 mg and 150 mg was associated with reduced mortality among patients with COVID-19 requiring respiratory support. 19) , has created an unprecedented infectious disease crisis worldwide. [1] [2] [3] [4] The RECOVERY (Randomized Evaluation of COVid-19 thERapY) trial, a randomized clinical trial examining a range of potential treatments for COVID-19, indicated that low-dose dexamethasone could reduce mortality in patients with COVID-19 requiring oxygen or mechanical ventilation support. 5 In that study, a total of 2104 patients were randomized to receive dexamethasone 6 mg once per day for 10 days, administered either orally or by intravenous injection, and were compared with 4321 patients randomized to usual care alone. Dexamethasone was significantly associated with reduced 28-day mortality in ventilated patients ( • In a multicentre observational study of patients hospitalized for COVID-19, we found that dexamethasone use administered either orally or by intravenous injection at a cumulative dose between 60 and 150 mg was associated with reduced mortality only in patients requiring respiratory support. effectiveness of a therapeutic option with greater external validity, i.e. in a population more closely resembling the target population, and in different subpopulations. 7, 8 Similar results from RCTs and observational studies can increase the confidence in the efficacy of a treatment, 9, 10 as suggested by a prior study that found little evidence that estimates of treatment effects in observational studies reported after 1984 are either consistently larger than or qualitatively different from those obtained in RCTs. 11 Specifically, if this observational study yielded similar results as those found in the RECOVERY trial, it would We used data from the AP-HP Health Data Warehouse (Entrepôt We obtained the following data for each patient at the time of hospital admission: sex, age, 10 obesity, current smoking status, any medical condition associated with increased risk of severe COVID-19, 10 Chemical terminology using approximate string matching. The endpoint was the time from study baseline to death. Patients without an end-point event had their data censored on 20 May 2020. Study baseline was defined as the date of hospital admission. Dexamethasone use was defined as receiving this medication orally or by intravenous injection at any time during the follow-up period, from study baseline to the end of the index hospitalization or death. Dexamethasone cumulative dose received was calculated and considered as a categorical variable with the following categories defined a priori: (i) 60-150 mg based on usual prescribing practice for acute respiratory distress syndrome in AP-HP hospitals (corresponding to 10 mg/d for 6 days, to 20 mg/d for 5 days followed by 10 mg/d for 5 days); (ii) other cumulative doses (i.e. >150 or <60 mg); and (iii) missing data. All analyses were stratified by the need for respiratory support, i.e. oxygen or mechanical ventilation, at any time during the follow-up. We calculated frequencies of each baseline characteristic described above in patients receiving and not receiving dexamethasone, and compared them using χ 2 tests. To examine the association of dexamethasone use with the endpoint, we performed Cox proportional-hazards regression models. To help account for the nonrandomized prescription of dexamethasone and reduce the effects of confounding, the primary analysis used a multivariable Cox regression model including as covariates sex, age, obesity, current smoking status, any medical condition associated with severe COVID-19, and clinical and biological markers of severe COVID-19 at admission. Weighted Cox regression models were used when the proportional hazards assumption was not met. Kaplan-Meier curves were performed and their pointwise 95% CIs were estimated using the nonparametric bootstrap method. 21 As a sensitivity analysis, we performed a univariate Cox regression model in a matched analytic sample using a 1:10 ratio, based on the same variables used for the multivariable Cox regression analysis. To reduce the effects of confounding, optimal matching was used in order to obtain the smallest average absolute distance across all clinical characteristics between exposed patient and nonexposed matched controls. We performed additional analyses. First, we examined whether the cumulative dose of dexamethasone received during the visit was associated with the endpoint of death. Second, we performed multivariable Cox regression models including interaction terms to examine whether the association between dexamethasone use and the endpoint significantly differed across baseline characteristics. For all associations, we performed residual analyses to assess the fit of the data, check assumptions, including proportional hazards assumptions, and examined the potential influence of outliers. To improve the quality of result reporting, we followed the recommendations of The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Initiative. 22 Statistical significance was fixed a priori at 2-sided P-value < .05. All analyses were conducted in R software version 2.4.3 (R Project for Statistical Computing). T A B L E 1 Characteristics of patients with or without respiratory support (oxygen or intubation) according to dexamethasone use Exposed to dexamethasone Not exposed to dexamethasone Nonexposed matched group Exposed to dexamethasone vs. not exposed to dexamethasone (crude analysis) Associations between baseline characteristics and the endpoint are given in Table S1 . The distribution of the patient characteristics by dexamethasone use is shown in Assessed using ICD-10 diagnosis codes for diabetes mellitus (E11), diseases of the circulatory system (I00-I99), diseases of the respiratory system (J00-J99), neoplasms (C00-D49), and diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D5-D8). d Defined as having at least 1 of the following criteria: respiratory rate >24 breaths/min or <12 breaths/min, resting peripheral capillary oxygen saturation in ambient air <90%, temperature >40 C, or systolic blood pressure < 100 mmHg. e Defined as having at least 1 of the following criteria: high neutrophil-to-lymphocyte ratio, low lymphocyte-to-C-reactive protein (both variables were dichotomized at the median of the values observed in the full sample), and plasma lactate >2 mmol/L. *P-value is significant (P < .05). among those who did not. In the matched analytic samples, there were no significant differences in patient characteristics according to dexamethasone use (Table 1 ). Among patients with COVID-19 who required respiratory support, Figure S1 ). Finally, the association between dexamethasone use and the endpoint did not significantly differ across subgroups defined by baseline characteristics in both groups with and without respiratory support, except for patients with obesity who did not require respiratory support, for whom dexamethasone use was significantly associated with increased mortality compared to obese patients without dexametha- showing that they can help decide which treatment should be prioritized for future RCTs and reduce the risk for patients of being exposed to potentially harmful and ineffective treatments in RCTs. [12] [13] [14] [15] Our study has several limitations. First, there are 2 possible major inherent biases in observational studies: unmeasured confounding and confounding by indication. Some amount of unmeasured confounding may remain. However, our analyses adjusted for numerous potential confounders, including sex, age, obesity, current smoking status, any medical condition associated with severe COVID-19, and clinical and biological markers of severe COVID-19 at admission. Second, there are missing data for some variables and potential for inaccuracies in the electronic health records, such as the possible lack of documentation of illnesses or medications, or the misidentification of treatment mode of administration (e.g. dose, frequency), especially for hand-written medical prescriptions. Third, our study cannot establish causal relationships. Finally, despite the multicentre design, our results may not be generalizable to outpatients or other regions. In this multicentre observational study, dexamethasone use administered either orally or by intravenous injection was associated with decreased mortality among adult patients hospitalized for COVID-19 requiring respiratory support. A stochastic agent-based model of the SARS-CoV-2 epidemic in France Facing the COVID-19 epidemic in NYC: a stochastic agent-based model of various intervention strategies. medRxiv Ensuring mental health care during the SARS-CoV-2 epidemic in France: A narrative review Impact of the timing and adherence to face mask use on the course of the COVID-19 epidemic in France Dexamethasone in Hospitalized Patients with Covid-19 Beyond dexamethasone, emerging immuno-thrombotic therapies for COVID-19 Randomized controlled trials vs. observational studies: why not just live together? Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report Entrepôt de Données de Santé Factors associated with COVID-19-related death using OpenSAFELY A comparison of observational studies and randomized, controlled trials Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry Association between Hydroxyzine Use and Reduced Mortality in Patients Hospitalized for Coronavirus Disease 2019: Results from a multicenter observational study. medRxiv Observational study of haloperidol in hospitalized patients with COVID-19 Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Statement on the Management at Home or in a Care Facility of Suspected or Confirmed Covid-19 Patients Neutrophil-to-lymphocyte ratio and lymphocyteto-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis BioBERT: a pre-trained biomedical language representation model for biomedical text mining Med-Ext: combining expert knowledge and deep learning for medication extraction from French clinical texts Nonparametric standard errors and confidence intervals The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies After 62 years of regulating immunity, dexamethasone meets COVID-19 High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19 Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study The authors thank the EDS AP-HP COVID consortium integrating the AP-HP Health Data Warehouse team as well as all the AP-HP staff and volunteers who contributed to the implementation of the EDS-COVID database and operating solutions for this database. Dr Hoertel has received personal fees and nonfinancial support from Lundbeck, outside the submitted work. Dr Limosin has received speaker and consulting fees from Janssen-Cilag outside the submitted work. Other authors declare no competing interests.